167 related articles for article (PubMed ID: 18384711)
1. Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Iwamoto J; Matsumoto H; Takeda T
Curr Med Res Opin; 2008 May; 24(5):1379-84. PubMed ID: 18384711
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population.
Iwamoto J; Takeda T; Matsumoto H
Curr Med Res Opin; 2011 Jun; 27(6):1141-8. PubMed ID: 21456887
[TBL] [Abstract][Full Text] [Related]
3. Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease.
Iwamoto J; Sato Y; Tanaka K; Takeda T; Matsumoto H
Aging Clin Exp Res; 2009; 21(4-5):277-81. PubMed ID: 19959915
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
Sato Y; Iwamoto J; Honda Y
J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1390-3. PubMed ID: 21825080
[TBL] [Abstract][Full Text] [Related]
5. Sunlight exposure is important for preventing hip fractures in patients with Alzheimer's disease, Parkinson's disease, or stroke.
Iwamoto J; Takeda T; Matsumoto H
Acta Neurol Scand; 2012 Apr; 125(4):279-84. PubMed ID: 21682695
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of menatetrenone (vitamin K2) against non-vertebral and hip fractures in patients with neurological diseases: meta-analysis of three randomized, controlled trials.
Iwamoto J; Matsumoto H; Takeda T
Clin Drug Investig; 2009; 29(7):471-479. PubMed ID: 19499964
[TBL] [Abstract][Full Text] [Related]
7. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
Masud T; McClung M; Geusens P
Clin Interv Aging; 2009; 4():445-9. PubMed ID: 19966913
[TBL] [Abstract][Full Text] [Related]
8. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Sato Y; Honda Y; Iwamoto J
Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Osaki M; Tatsuki K; Hashikawa T; Norimatsu T; Chiba K; Motokawa S; Furuichi I; Doiguchi Y; Aoyagi K; Shindo H
Osteoporos Int; 2012 Feb; 23(2):695-703. PubMed ID: 21394496
[TBL] [Abstract][Full Text] [Related]
11. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Neurology; 2005 Mar; 64(5):811-6. PubMed ID: 15753414
[TBL] [Abstract][Full Text] [Related]
12. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
13. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.
Sato Y; Iwamoto J; Kanoko T; Satoh K
Arch Intern Med; 2005 Aug 8-22; 165(15):1743-8. PubMed ID: 16087822
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Boonen S; Klemes AB; Zhou X; Lindsay R
J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
[TBL] [Abstract][Full Text] [Related]
15. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Boonen S; Laan RF; Barton IP; Watts NB
Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
[TBL] [Abstract][Full Text] [Related]
16. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
17. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
18. Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Poole KE; Warburton EA; Reeve J
Neurology; 2005 Nov; 65(9):1513-4; author reply 1513-4. PubMed ID: 16275859
[No Abstract] [Full Text] [Related]
19. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Sato Y; Honda Y; Umeno K; Hayashida N; Iwamoto J; Takeda T; Matsumoto H
Kurume Med J; 2011; 57(4):117-24. PubMed ID: 21778673
[TBL] [Abstract][Full Text] [Related]
20. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Zhong ZM; Chen JT
Clin Drug Investig; 2009; 29(5):349-57. PubMed ID: 19366276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
